On 15th April 2025, the European Commission authorised lecanemab (monoclonal anti-amyloid (beta) antibody; trade name: Leqembi from Eisai and Biogen) in the European Union to treat early Alzheimer’s disease. A decision was long awaited after the positive opinion on the marketing authorisation of the medicine by the European Medicines Agency (EMA) in November 2024. The […]

The EUROIMMUN Anti-Acetylcholine Receptor ELISA shows a high overall concordance with traditional radioimmunoassay (RIA) in patients with myasthenia gravis (MG), while offering advantages such as avoidance of radioisotope waste. This was the conclusion of a study on patients in Japan, which was performed as part of a collaboration between EUROIMMUN and scientists at the Neurology

A multiparameter EUROLINE blot for detection of myositis-related autoantibodies showed a high agreement with muscle biopsy results in patients with idiopathic inflammatory myopathies (IIM), suggesting it can be used as a first-line diagnostic tool in the diagnostic workflow. The recently published study was performed as part of a collaboration between scientists from EUROIMMUN Brazil and

The frequency of intrathecal antibody production to Epstein-Barr virus (EBV) in multiple sclerosis (MS) patients is surprisingly low compared to that of other microbial agents. This was shown in a collaborative study between EUROIMMUN and scientists at Charité Universitätsmedizin Berlin. The finding is intriguing given the strong link between EBV and MS. EBV is presumed

A new study has shown that mRNA vaccines against SARS-CoV-2 do not induce short-term worsening of autoimmunity in patients with autoimmune liver diseases (AILD). The collaborative study between EUROIMMUN and researchers at the Epatocentro Ticino, Lugano and other institutes and clinics in Switzerland was published recently in the Journal of Autoimmunity. The mRNA vaccines against